Pharmaceutical combination products comprising a histone deacetylase (HDAC) inhibitor and a TLR7 agonist and/or TLR8 agonist for the treatment of cancer
The invention relates to pharmaceutical combination products comprising an HDAC inhibitor, e.g. (E)-N-(2-amino-phenyl)-3-{1-[4-(1-methyl-1H-pyrazol-4-yl)-benzenesulfonyl]-1H-pyrrol-3-yl}- acrylamide as well as salts and or solvents thereof and TLR7 agonist and/or TLR8 agonist for the treatment of cancer. The present invention also relates to methods of treatment of patients suffering from cancer with these pharmaceutical combination products.
